Danielle Mejias, NP
Community Health · Binghamton, NYNPI 1811665789
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.
Across 46 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$175
- Lilly USA, LLC$167
- Inspire Medical Systems, Inc.$87
- Antares Pharma, Inc.$72
- Dexcom, Inc.$57
- Cequr Corporation$53
- plus $435 from 18 others
What the payments were for
- Food & beverage$1,03499%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 4 | $175 |
| Lilly USA, LLC | 7 | $167 |
| Inspire Medical Systems, Inc. | 4 | $87 |
| Antares Pharma, Inc. | 4 | $72 |
| Dexcom, Inc. | 3 | $57 |
| Cequr Corporation | 2 | $53 |
| Sequel Med Tech, LLC | 2 | $41 |
| Bayer | 2 | $36 |
| Boehringer Ingelheim | 2 | $36 |
| Itamar Medical Inc | 1 | $34 |
| Radius Health, Inc. | 1 | $33 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $29 |
| Abbott | 1 | $24 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $17 |
| AbbVie | 1 | $16 |
| Fisher & Paykel Healthcare Inc | 1 | $16 |
| Amgen | 1 | $15 |
| Insulet Corporation | 1 | $14 |
How this compares
$1,045 in reported general payments places this provider in the 85th percentile of 21 community health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 434 | $894,999 |
| MounjaroTirzepatide | 495 | $587,863 |
| JardianceEmpagliflozin | 325 | $463,681 |
| TrulicityDulaglutide | 189 | $323,924 |
| Tresiba Flextouch U-100Insulin Degludec | 138 | $152,806 |
| FarxigaDapagliflozin Propanediol | 97 | $125,337 |
| JanuviaSitagliptin Phosphate | 68 | $92,982 |
| Tresiba Flextouch U-200Insulin Degludec | 58 | $84,995 |
| RybelsusSemaglutide | 33 | $78,790 |
| Novolog FlexpenInsulin Aspart | 211 | $73,579 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 377 | $70,140 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $65,700 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 136 | $58,377 |
| TradjentaLinagliptin | 52 | $57,464 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 124 | $57,365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $175 | $988,861516 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $167 | $932,183755 claims |
| Boehringer IngelheimJardiance, Tradjenta | $36 | $521,145377 claims |
| AbbVieCreon | $16 | $17,24911 claims |
| Sanofi-aventis U.S. LLCLantus | $20 | $3,04414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 21 community health providers in New York.
Other community health in Binghamton
- Scott RosmanBinghamton$13K
- Stacey RosmanBinghamton$457
- Terry HardingBinghamton$23
- Edwin TorresNew York$76K
- Sharon PearceDolgeville$3K
- Megan CoghlanSyracuse$529
- Desiree DarrisawNew York$506
- Mallory FurnissWest Amherst$442
- Dayle BowerVestal$416
- Dawn LawyerNew York$305
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.